ADVFN - Advanced Financial Network.
HOME» NASDAQ » G » GILD Stock Price » GILD Stock News

Gilead Sciences Share News

 Gilead Sciences (mm) Stock Price
GILD Stock Price
 Gilead Sciences (mm) Stock Chart
GILD Stock Chart
 Gilead Sciences (mm) Stock News
GILD Stock News
 Gilead Sciences (mm) Company Information
GILD Company Information
 Gilead Sciences (mm) Stock Trades
GILD Stock Trades

Gilead Sciences to Promote Low-Cost HIV Medicine in Developing World

By Chelsea Stevenson Gilead Sciences Inc. (GILD) said it plans to partner with Mylan Inc. (MYL), Ranbaxy Laboratories Ltd. (500359.BY) and Strides Arcolab Ltd. (532531.BY) to promote access to high-quality, low-cost generic versions of Gilead's HIV medicine emtricitabine in developing countries. The medicine includes single tablet regimens and fixed-dose combinations of emtricitabine co-formulated with other Gilead HIV medicines. Under the new agreement, Gilead will provide a technology transfer for the manufacture of emtricitabine as well as funding to reduce overall manufacturing costs. Emtricitabine is marked by Gilead under the name Emtriva and the fixed-dose is available under the name Truvada. But costs are an obstacle for high-volume production. More than 2.7 million patients living with HIV in developing countries are currently receiving a medicine innovated by Gilead and subsequently licensed to Indian generic partners, as part of the company's efforts to increase global access. Strides Arcolab Managing Director Arun Kumar said the partnership will also re-enforce commitments to provide affordable drugs in the tuberculosis and malaria fields. Gilead's second-quarter earnings slid last week as the company posted a double-digit increase in costs, which offset its strong revenue growth. Earlier this year, the company bought Pharmasset Inc. for more than $11 billion, expecting the company to help accelerate the development of treatments for hepatitis C. Write to Chelsea Stevenson at Subscribe to WSJ:

Stock News for Gilead Sciences (GILD)
10/25/201608:20:00Merck Profit Rises on Cancer Drugs, Vaccines
10/24/201617:00:00Gilead Sciences to Present at the Credit Suisse 25th Annual Healthcare...
10/24/201606:24:00Gilead Presents Results from Phase 3 Studies Evaluating Switching...
10/20/201610:07:00Gilead Announces SVR12 Rates From Four Phase 3 Studies of a Once-Daily...
10/20/201610:05:00Gilead Announces Top-Line Phase 2 Results for GS-4997 (Selonsertib...
10/06/201612:30:00Singapore's Temasek Hires Veteran Goldman Banker
10/05/201612:54:17Statement of Changes in Beneficial Ownership (4)
10/04/201618:03:00FDA Warns on Hepatitis C Drugs
10/03/201619:53:39Statement of Changes in Beneficial Ownership (4)
09/27/201616:05:00Gilead Sciences and the World Health Organization Announce Five-Year...
09/26/201616:56:18Statement of Changes in Beneficial Ownership (4)
09/21/201619:05:00Gilead Sciences Halts Test of Bowel Disease Treatment
09/21/201617:00:00Gilead Terminates Phase 2/3 Study of GS-5745 in Patients With...
09/20/201617:09:06Current Report Filing (8-k)
09/19/201616:47:49Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)
09/16/201606:06:02Free Writing Prospectus - Filing Under Securities Act Rules 163/433...
09/15/201622:01:00Gilead Prices $5 Billion of Senior Unsecured Notes
09/15/201608:58:00Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)
09/13/201610:25:57Confidential Treatment Order (ct Order)
09/13/201600:30:00Scientists Honored for Hep C Research

Gilead Sciences and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations